How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comPhase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer
Description:
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Sponsor:
Radionetics Oncology
Phase:
Phase 1
Contacts:
Yael Cohen-Arazir10602-101@radionetics.com
858-373-7793
Kristrun Stardalr10602-101@radionetics.com
949-887-9494
Government Study Link:
NCT06745804 - Click here to see study onClinicalTrials.gov
68Ga-R10602
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- G protein-coupled receptors (GPCRs)
Share your feedback
Help us improve your experience